Cost-utility analysis of drugs for secondary bone fracture prevention among post-menopausal osteoporotic patients in Thailand
Author:
Date:
2021
Publisher:
Silpakorn University
Abstract:
This study assessed the cost utility of medications used to prevent recurrent bone fractures among post-menopausal osteoporotic Thai women with a history of fractures.Economic evaluation was conducted using the Markov model-based cost-utility analysis approachunderthe societal perspective. Women age 50 and over with bone mass density T-score of less than or equal to 2.5 standard deviationsand a history of fractures were included in the model, with a 1-year cycle length, until deceased. The model compared theexpected costs and outcomes of calcium plus vitamin Dalone (standard regimen) with those of calcium plus vitamin D with adjunct bisphosphonates (alendronateorrisedronate), raloxifene, strontium, denosumab,orteriparatide.Bisphosphonates providedaddedhealth benefits whereas the other drugs did not. The incremental cost-effectiveness ratio (ICER) per quality-adjusted life year (QALY) gained wereapproximately 92,995Baht(US$2,997) forbisphosphonates and 1,701,932Baht(US$54,848) for denosumab. Teriparatide was the most expensive with an ICER of 10,354,673Baht(US$333,699) per QALY gained.The cost of drugs was the major expense.In conclusion, bisphosphonatesare themost cost-effective adjunct interventions for post-menopausal osteoporotic women with a history of fractures treated under the Thai healthcare system
Description:
Published in : Science, Engineering and Health Studies Volume 15, 2021, p.1-9
Type:
Rights Holder:
มหาวิทยาลัยศิลปากร
Collections:
Total Download:
87

